UBS lowered the firm’s price target on Alkermes (ALKS) to $33 from $38 and keeps a Neutral rating on the shares. Alkermes’ Q1 was soft-guided, and UBS notes crowding of orexin read-outs in the second half of 2025, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Balanced Assessment of Alkermes: Hold Rating Justified by Stable Valuation and Orexin Program Potential
- Alkermes initiates Phase 2 study evaluating ALKS 2680 in idopathic hypersomnia
- Alkermes price target raised to $52 from $40 at Deutsche Bank
- Alkermes price target raised to $35 from $34 at BofA
- Alkermes initiated with a Sector Perform at RBC Capital